SCHEMBL7162719

SCHEMBL7162719

NCCN(C(=O)c1ccc2c(c1)CN(CCc1ccccc1)C(=O)C(CC(=O)O)N2)c1ncc[nH]1

nearest known ligand 0.60

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ ITGB3 P05106 20/20 0.60
▸ ITGA2B P08514 12/20 0.60
▸ ITGAV P06756 10/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5972979 0.79 ITGB3 (0.55) ITGB3ITGA2BITGAV
SCHEMBL7329363 0.79 ITGB3 (0.76) ITGB3ITGA2BITGAV
SCHEMBL6674672 0.79 ITGB3 (0.71) ITGB3ITGA2BITGAV
SCHEMBL7079853 0.79 ITGB3 (0.71) ITGB3ITGA2BITGAV
SCHEMBL6674674 0.79 ITGB3 (0.71) ITGB3ITGA2BITGAV
SCHEMBL7162722 0.78 ITGB3 (0.78) ITGB3ITGA2BITGAV
SCHEMBL7162734 0.77 ITGB3 (0.59) ITGB3ITGA2BITGAV
SCHEMBL8468526 0.76 ITGB3 (0.77) ITGB3ITGA2BITGAV
SCHEMBL8465392 0.75 ITGB3 (0.86) ITGB3ITGA2BITGAV
SCHEMBL8468639 0.75 ITGB3 (0.68) ITGB3ITGA2BITGAV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0946180-A4 METHOD FOR STIMULATING BONE FORMATION SMITHKLINE BEECHAM CORP (US) 2003-07-23 — — EP disclosed
US-20020032187-A1 Method for stimulating bone formation SMITHKLINE BEECHAM CORPORATION 2002-03-14 — — US disclosed
EP-0946180-A1 METHOD FOR STIMULATING BONE FORMATION SMITHKLINE BEECHAM CORPORATION (US) 1999-10-06 — — EP disclosed
WO-1998015278-A1 METHOD FOR STIMULATING BONE FORMATION SMITHKLINE BEECHAM CORPORATION (US) 1998-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032187-A1 Method for stimulating bone formation BMP2, BMP4, SOST ITGB3 11/4885ITGA2B 13/4885ITGAV 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback